Computer-Aided Discovery, Validation, and Mechanistic Characterization of Novel Neolignan Activators of Peroxisome Proliferator-Activated Receptor γ
Open Access
- 11 January 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 77 (4), 559-566
- https://doi.org/10.1124/mol.109.062141
Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) agonists are used for the treatment of type 2 diabetes and metabolic syndrome. However, the currently used PPARγ agonists display serious side effects, which has led to a great interest in the discovery of novel ligands with favorable properties. The aim of our study was to identify new PPARγ agonists by a PPARγ pharmacophore–based virtual screening of 3D natural product libraries. This in silico approach led to the identification of several neolignans predicted to bind the receptor ligand binding domain (LBD). To confirm this prediction, the neolignans dieugenol, tetrahydrodieugenol, and magnolol were isolated from the respective natural source or synthesized and subsequently tested for PPARγ receptor binding. The neolignans bound to the PPARγ LBD with EC50 values in the nanomolar range, exhibiting a binding pattern highly similar to the clinically used agonist pioglitazone. In intact cells, dieugenol and tetrahydrodieugenol selectively activated human PPARγ-mediated, but not human PPARα- or -β/δ-mediated luciferase reporter expression, with a pattern suggesting partial PPARγ agonism. The coactivator recruitment study also demonstrated partial agonism of the tested neolignans. Dieugenol, tetrahydrodieugenol, and magnolol but not the structurally related eugenol induced 3T3-L1 preadipocyte differentiation, confirming effectiveness in a cell model with endogenous PPARγ expression. In conclusion, we identified neolignans as novel ligands for PPARγ, which exhibited interesting activation profiles, recommending them as potential pharmaceutical leads or dietary supplements.Keywords
This publication has 34 references indexed in Scilit:
- Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cellsLife Sciences, 2009
- ‘Striking the Right Balance’ in Targeting PPARγ in the Metabolic Syndrome: Novel Insights from Human Genetic StudiesPPAR Research, 2007
- Natural Products as Sources of New Drugs over the Last 25 YearsJournal of Natural Products, 2007
- Targeting Components of the Stress System as Potential Therapies for the Metabolic SyndromeAnnals of the New York Academy of Sciences, 2006
- Effects of magnolol (5,5′-diallyl-2,2′-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto–Kakizaki ratsLife Sciences, 2006
- Antimutagenic Activity of Phenylpropanoids from Clove (Syzygium aromaticum)Journal of Agricultural and Food Chemistry, 2003
- Antioxidant Activity of Eugenol and Related Monomeric and Dimeric Compounds.CHEMICAL & PHARMACEUTICAL BULLETIN, 2000
- The Protein Data BankNucleic Acids Research, 2000
- PPAR-RXR Heterodimer Activates a Peroxisome Proliferator Response Element Upstream of the Bifunctional Enzyme GeneBiochemical and Biophysical Research Communications, 1993
- Isolation and Characterization of Phenolic Compounds from Magnoliae Cortex Produced in China.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991